Longevity: what are the top startups now?
In our longevity market deck, you will find everything you need to understand the market
SUMMARY
What are the top startups in the longevity market? The top longevity startups are NewLimit, Life Biosciences, Loyal, Function Health, Neko Health, Retro Biosciences, Rubedo Life Sciences, Timeline, Superpower, Rejuvenate Bio, and Aeovian, but they lead for very different reasons.
The market is no longer one simple “anti-aging” category. It has split into four real leaderboards: moonshot reprogramming, clinical aging biology, animal longevity, and consumer healthspan.
The strongest biotech signal is not hype anymore, but proximity to humans. Life Biosciences stands out because first human dosing for partial epigenetic reprogramming is a more concrete milestone than platform ambition, even if the initial indication is narrow.
NewLimit has the biggest fresh capital signal, but not the strongest public human evidence. Its $435 million Series C makes it the best-funded current reprogramming bet, while Life Biosciences still looks more advanced on clinical execution.
Loyal is the clearest near-commercial longevity company because it chose dogs first. That makes the biology less directly human, but the regulatory-commercial path is much more realistic than most human longevity therapeutics.
Consumer longevity is becoming a product category faster than therapeutic longevity is becoming a drug category. Function Health, Neko Health, Superpower, Timeline, and TruDiagnostic/Tally Health are not proving lifespan extension, but they are proving demand for preventive, measurable, repeatable healthspan products.
Function Health and Neko Health are the two cleanest consumer breakouts, but their models are not the same. Function scales through repeated biomarker testing and software, while Neko is trying to scale a premium physical preventive-health experience.
Rubedo is one of the most underappreciated names because senolytics became less fashionable before the company produced fresh human data. Its advantage is not narrative; it is a practical dermatology wedge with early clinical evidence.
Retro Biosciences remains a top moonshot, but the public evidence is stronger on AI-enabled biology than on clinical execution. Its OpenAI-linked reprogramming result is specific and interesting, yet still upstream from patient proof.
The most famous names are not automatically the strongest current names. Altos Labs still has deep scientific prestige, but newer public signals from Life Biosciences, NewLimit, Retro, Function, Loyal, and Rubedo are easier to verify.
The broader pattern is that the best longevity startups now either have fresh regulated evidence, visible consumer adoption, closed financing at serious scale, or strategic validation from a credible incumbent. The weaker ones still rely mostly on reputation, biological-age claims, mouse data, or vague “live longer” branding.
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
Which longevity startups are actually closest to proving something in humans?
Life Biosciences, Rubedo Life Sciences, Aeovian, NewLimit, and Retro Biosciences are the strongest clinical group today, but they are not equally advanced.
Life Biosciences is currently the cleanest answer because it crossed the most important line in longevity biotech: first human dosing for a partial epigenetic reprogramming therapy. In June 2026, the company dosed the first participant in a Phase 1 trial of ER-100 for optic neuropathies, including glaucoma and NAION. That puts Life Biosciences ahead of better-known reprogramming names because it is now testing human safety rather than only publishing animal biology or raising platform capital.
Rubedo comes second on actual human evidence. Its April 2026 preliminary Phase 1 results for RLS-1496 matter because senolytics have been talked about for years, but very few companies have produced fresh human data. Rubedo’s advantage over more famous senescence startups is not brand awareness. It is that the company has a tractable topical route, measurable dermatology endpoints, and a Phase 1 signal tied to target engagement and clinical improvement.
Aeovian is more conventional, but that is exactly why it deserves to be ranked here. In December 2025, it raised $55 million to complete a Phase 2 proof-of-concept study of AV078, a selective mTORC1 inhibitor for TSC-related refractory epilepsy. Compared with reprogramming startups, Aeovian is less spectacular. Compared with most “aging pathway” startups, it is further along clinically and has a cleaner disease wedge.
NewLimit has the strongest momentum before the clinic. Its June 2026 $435 million Series C gives it more near-term firepower than Life Biosciences or Rubedo, but the company is still behind them on public human evidence. This is the core distinction: NewLimit may be the better-capitalized company, while Life Biosciences and Rubedo currently have the more concrete clinical proof points.
Retro Biosciences remains a serious contender, but we would rank it behind Life Biosciences on clinical transparency. Retro has the Sam Altman backing, a reported $1 billion Series A effort, and plans to move an Alzheimer’s/autophagy candidate into trials.
The gap is that its freshest public signal is stronger on AI-enabled biology than on confirmed clinical execution.
If you want more recent data on this point, please see our latest longevity market report.
Which reprogramming startups are really leading the reverse-aging race?
Life Biosciences, NewLimit, Retro Biosciences, and Altos Labs lead reprogramming, with Life Biosciences winning on human timing and NewLimit winning on capital velocity.
Life Biosciences is the current execution leader because it moved partial reprogramming into a human trial first. That gives it a sharper near-term readout than Altos or Retro, even if its first indication is narrow. The market should treat that distinction seriously: a small Phase 1 ophthalmology study does not prove systemic rejuvenation, but it tests whether epigenetic restoration can be delivered safely in humans. That is a harder signal than a large platform narrative.
NewLimit is the strongest “next wave” reprogramming startup. Its $435 million Series C in June 2026 is unusually large for a private biotech in today’s funding environment, and the reported $3.1 billion valuation puts it in a different league from normal preclinical companies. The valuation only makes sense if investors believe the company has built a credible path from cellular reprogramming screens to disease programs. Still, compared with Life Biosciences, NewLimit is currently more of a high-conviction future-clinic bet than a human-trial leader.
Retro Biosciences is the AI-reprogramming wildcard. Its OpenAI collaboration reported more than a 50x increase in stem-cell reprogramming marker expression using GPT-4b micro-designed Yamanaka-factor variants. That is a specific technical signal, and it is more interesting than generic “AI for biotech” language. But it remains upstream from clinical proof: a better reprogramming factor in the lab is not the same thing as safe tissue rejuvenation in a patient.
Altos Labs still has the deepest prestige base in the category. Its $3 billion launch in 2022, elite scientific hires, and focus on cellular rejuvenation keep it in the top group. The reason we do not put it first right now is simple: the latest public signals from Life Biosciences and NewLimit are easier to verify. Altos may still have the strongest internal science, but it is not giving the market the most current external evidence.
The ranking is therefore clearer than the hype suggests: Life Biosciences first for first-in-human execution, NewLimit second for fresh capital intensity, Retro third for AI-enabled technical progress, and Altos as the powerful but opaque incumbent.
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Which longevity startups have the strongest funding signal today?
NewLimit, Function Health, Neko Health, Retro Biosciences, Life Biosciences, and Superpower stand out, but the funding signal means different things in each case.
NewLimit is the top biotech funding signal right now. A $435 million Series C in June 2026 is not just “large.” It is larger than many public biotech follow-ons and far above what most preclinical longevity companies can raise. Compared with Life Biosciences, NewLimit has less public human evidence, but the financing tells us investors are underwriting a broader platform and a faster push into multiple aging-related programs.
Function Health is the top consumer-healthspan funding signal. In November 2025, it announced a $298 million Series B at a $2.5 billion valuation. That is smaller than NewLimit’s round but more commercially revealing, because Function also disclosed “hundreds of thousands” of members. In other words, Function’s valuation is attached to visible consumer demand, while NewLimit’s valuation is attached to biotech platform risk.
Neko Health is the better comparison point for Function than any therapeutic biotech. In January 2025, Neko raised $260 million and disclosed 10,000 completed scans plus a waiting list above 100,000 people. Function looks stronger on recurring lab-data scale. Neko looks stronger on premium preventive-care experience and clinic throughput. Both are hot, but they are proving different consumer behaviors.
Retro Biosciences has the biggest ambition signal but less funding certainty. Reports in January 2025 said it was raising a $1 billion Series A after Sam Altman’s earlier $180 million backing. We would not treat a reported raise the same way as a closed round. Still, Retro belongs in the top funding conversation because very few longevity startups can even credibly attempt a billion-dollar private financing.
Superpower is the emerging name we would not ignore. Its April 2025 $30 million raise is tiny next to Function’s or Neko’s, but the product is priced at $499 per year and includes biannual testing across more than 100 biomarkers. The comparison is useful: Function is already the premium-scale platform; Superpower is trying to compress a similar healthspan idea into a more accessible consumer subscription.
Which startups are turning longevity into a real consumer product?
Function Health, Neko Health, Superpower, Timeline, and TruDiagnostic/Tally Health are the relevant pack, with Function currently in front.
Function Health is the consumer longevity leader because it combines scale, valuation, and a clear product habit. The strongest signal is not only its $2.5 billion valuation. It is the combination of that valuation with hundreds of thousands of members and an AI interpretation layer launched in November 2025. Compared with Neko, Function is easier to repeat regularly because blood testing and data interpretation fit a subscription rhythm.
Neko Health is the premium physical-exam challenger. Its 10,000 completed scans and 100,000-person waiting list show unusually strong demand for preventive healthcare. But compared with Function, Neko has more operational friction: clinics, equipment, medical staff, and regulatory expansion. That makes its demand signal impressive, while also making scale harder.
Superpower is the one to watch lately at the lower-cost end. Its $499 annual price and broad biomarker panel put it closer to a mass consumer healthspan product than Neko. The reason we rank it behind Function is evidence depth: we have a funding round and a product spec, but not yet member count, retention, revenue, or clinical-outcome data.
Timeline is the strongest evidence-based supplement company in the group. Most supplement brands rely on influencer distribution or vague biological-age claims. Timeline has a sharper claim because Mitopure has reached 25 human clinical studies and more than 2,200 research participants. That does not make Timeline a therapeutics company, but compared with other nutrition-led longevity brands, its evidence base is materially stronger.
TruDiagnostic/Tally Health is the consolidation signal. Infinite Epigenetics’ April 2026 acquisition of Tally Health suggests biological-age testing is moving from scattered DTC kits toward larger methylation-data platforms. We would still rank it below Function and Neko on consumer momentum, because epigenetic age is useful but not yet as behaviorally obvious as repeated blood testing or a premium preventive scan.
If you want more recent data on this point, please see our latest longevity market report.
This chart, featured in our longevity market deck, illustrates yearly VC funding for longevity startups
Which longevity startups are closest to a regulated commercial product?
Loyal, Life Biosciences, Rubedo, Aeovian, and Rejuvenate Bio are the strongest candidates, with Loyal clearly ahead on near-term commercialization.
Loyal is first because it has the most concrete regulatory-commercial bridge. In February 2025, FDA CVM accepted the reasonable-expectation-of-effectiveness section for LOY-002, its senior-dog lifespan-extension pill. That does not equal final approval, but it is much closer to market than most human longevity programs. Compared with Life Biosciences, Loyal’s biology is less radical, yet its path to launch is more realistic.
Life Biosciences is the opposite profile: more scientifically ambitious, less commercially near-term. Its June 2026 first human dosing makes it the top human rejuvenation milestone, but Phase 1 ophthalmology is still early. If Loyal is the regulatory frontrunner, Life Biosciences is the highest-upside human clinical proof-of-concept candidate.
Rubedo sits between them. Its topical senolytic approach is less futuristic than reprogramming, but the dermatology wedge makes clinical development more manageable. Compared with Life Biosciences, Rubedo has a smaller conceptual ceiling. Compared with many senolytic peers, it has fresher human data and a clearer next study path.
Aeovian is credible because it is not trying to sell aging as an indication. AV078 targets TSC-related refractory epilepsy, while the underlying biology, selective mTORC1 inhibition, sits inside one of the best-known longevity pathways. That makes Aeovian more drug-development disciplined than companies that lead with anti-aging branding.
Rejuvenate Bio is earlier, but its June 2026 collaboration with Merck Animal Health gives it a real strategic signal. A $6 million round alone would not put it in this section. Merck’s participation changes the reading: targeted gene therapy for age-associated disease in animals is interesting enough for an incumbent animal-health company to engage.
Which startups are strongest in animal longevity?
Loyal is the clear leader in animal longevity, with Rejuvenate Bio emerging as the technical challenger.
Loyal is ahead by a wide margin because it has repeated regulatory validation in the exact category others still describe conceptually: lifespan-extension drugs. Its senior-dog program, LOY-002, received FDA CVM reasonable-expectation-of-effectiveness acceptance in February 2025, and the company had already reached a similar milestone for LOY-001 in large dogs. Compared with any other animal-longevity startup, Loyal has the strongest combination of regulatory path, consumer clarity, and near-market positioning.
Rejuvenate Bio is the more technically ambitious challenger. Rather than developing a pill for senior dogs, it is building gene therapies for age-related and chronic diseases. The June 2026 Merck Animal Health collaboration is the evidence that makes it worth ranking: without that, Rejuvenate Bio would look too early and too small relative to Loyal.
There is no honest top three or top five here. The category is still thin. Animal longevity is hot because dogs offer shorter development cycles, motivated owners, and a clearer regulatory path than humans, but today’s evidence points to one leader and one emerging challenger.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Which startups are most credible in diagnostics and biological age testing?
Function Health, Neko Health, TruDiagnostic/Tally Health, Viome, and Superpower stand out, but Function and Neko are pulling away from the rest.
Function Health is winning the biomarker operating-system layer. Its advantage over Superpower is not that it tests more interesting biomarkers; both are packaging broad lab testing for consumers. Function is ahead because it has disclosed far stronger scale and funding signals: hundreds of thousands of members and a $2.5 billion valuation. That gives it a larger data loop, more brand trust, and more room to build the AI interpretation layer.
Neko Health leads the scan-based layer. Compared with Function, it captures a more premium visit and a more memorable health experience. The tradeoff is that Neko must scale clinics while Function can scale through lab networks and software. That is why Function looks more scalable today, while Neko looks more differentiated physically.
TruDiagnostic/Tally Health is the biological-age-testing consolidation play. The April 2026 acquisition matters because this market has too many standalone kits and too little trust. Combining TruDiagnostic’s lab and analytics infrastructure with Tally’s consumer brand could create a stronger methylation-data platform. Still, we would rank it below Function and Neko because biological-age testing remains harder to translate into immediate consumer action.
Viome remains relevant because it works across microbiome, gene expression, and personalized nutrition. The issue is that Viome has been around long enough that “AI-powered recommendations” no longer feels fresh by itself. It needs newer outcome data or clearer diagnostic adoption to regain momentum.
Superpower is the accessible challenger. At $499 per year for biannual testing across more than 100 biomarkers, it attacks a real affordability gap. We rank it below Function because we have less proof of scale, but it could become the sharper consumer brand if price and simplicity matter more than clinical depth.
If you want more recent data on this point, please see our latest longevity market report.
Which longevity startups are using AI in a way that is more than marketing?
Retro Biosciences, Function Health, NewLimit, Viome, and Insilico Medicine are the most credible AI-linked names, but Retro has the sharpest technical proof point.
Retro Biosciences stands out because its OpenAI collaboration produced a specific biological result: GPT-4b micro-designed Yamanaka-factor variants reportedly drove more than a 50x increase in stem-cell reprogramming marker expression. That is far more concrete than saying “AI accelerates discovery.” Compared with Function or Viome, Retro is using AI closer to the biology itself, not just the interpretation layer.
Function Health is the strongest AI application at the consumer interface. Its Medical Intelligence Lab matters because consumer healthspan has a bottleneck: people can now generate far more lab data than they can interpret. Compared with Superpower, Function has more scale behind that AI layer, which matters because longitudinal biomarker data should improve personalization over time.
NewLimit likely depends on machine learning for perturbation design, cell-state measurement, and target discovery, but its public AI evidence is less explicit than Retro’s. That is why we rank NewLimit higher as a reprogramming company than as an AI proof-point company. The company may be deeply AI-native internally, but we should not overclaim what is not publicly shown.
Viome has a credible AI story because its product sits on complex multi-omic interpretation. The weakness is freshness. In today’s market, AI health interpretation is becoming table stakes, so Viome needs newer proof of clinical utility or adoption to stand above Function.
Insilico Medicine is relevant but adjacent. It raised $110 million in 2025 and applies AI drug discovery to aging-related diseases, among other areas. We would not call it a pure longevity startup anymore. It is better understood as an AI drug-discovery company with longevity exposure.
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Which startups are emerging fast but still under-discussed?
Rubedo Life Sciences, Rejuvenate Bio, Superpower, Aeovian, TruDiagnostic/Tally Health, and Midi Health are the names we would surface before they become obvious.
Rubedo is the most under-discussed biotech in this market. The reason is simple: senolytics became less fashionable just as Rubedo started producing human evidence. Compared with NewLimit or Retro, Rubedo looks less glamorous. Compared with most aging-biology startups, its April 2026 Phase 1 signal is more concrete.
Rejuvenate Bio is small, but the strategic signal is new and fresh. A $6 million financing would normally be too small for this list; the Merck Animal Health collaboration makes it different. Against Loyal, Rejuvenate Bio is much earlier. Against other animal-longevity gene-therapy startups, it now has the best incumbent validation we found.
Superpower is emerging because it attacks the same consumer desire as Function at a lower price point and with simpler packaging. It does not yet beat Function on scale, but it may be closer to what a mainstream user expects from a “longevity app”: labs, dashboard, protocols, repeat.
Aeovian is under-discussed because its lead indication does not scream longevity. That makes it more interesting, not less. The company is testing a selective version of one of the most validated aging pathways through a normal clinical route. Compared with many longevity-branded startups, Aeovian has less marketing heat and more drug-development discipline.
TruDiagnostic/Tally Health belongs here because consolidation is often the first sign that a category is leaving hype mode. The biological-age-testing market has been noisy for years. A platform that controls lab infrastructure, methylation analytics, and a consumer brand is more strategically meaningful than another standalone test.
Midi Health is a boundary case, but a useful one. It is not a classical longevity startup. Yet its October 2025 disclosure of roughly 20,000 patients served weekly and a $150 million annual revenue run rate makes it one of the strongest practical healthspan businesses, especially for midlife women. Compared with elite longevity clinics, Midi is less glamorous but more operationally real.
If you want more recent data on this point, please see our latest longevity market report.
Which famous longevity startups look less exciting right now?
Altos Labs, Cambrian Bio, BioAge Labs, and most supplement-first brands still matter, but their latest public signals are weaker than the newer clinical, regulatory, and consumer breakouts.
Altos Labs remains scientifically important, but it is too opaque to rank as the hottest startup today. Its original $3 billion launch still dwarfs almost everyone, yet current ranking should reward fresh evidence. Life Biosciences has first human dosing. NewLimit has a massive fresh round. Retro has a specific OpenAI biology signal. Altos may have stronger internal progress, but the public evidence is less current.
Cambrian Bio is credible but less visible. Its multi-asset aging-biology model made sense when the market rewarded broad longevity platforms. Lately, the strongest signals are narrower: one clinical trial, one regulatory milestone, one consumer product with visible demand. Cambrian needs a fresh asset-level milestone to re-enter the top tier.
BioAge Labs is the cautionary example. It entered public markets with a strong aging-biology narrative, but its obesity program was stopped after liver-safety concerns around azelaprag in late 2024 and the asset was discontinued in January 2025. That does not erase the company’s platform, but it shows why we now rank startups with cleaner safety and clinical momentum above companies with older platform stories.
Most supplement-first brands are also weaker than they look unless they bring human data. Timeline is the exception because it has a deeper Mitopure clinical-research base. For the rest, the bar has risen: a biological-age claim, mouse study, or influencer-led distribution is no longer enough to look like a top longevity startup.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
So which longevity startups are actually the top ones now?
The top longevity startups right now are NewLimit, Life Biosciences, Loyal, Function Health, Neko Health, Retro Biosciences, Rubedo Life Sciences, Timeline, Superpower, Rejuvenate Bio, and Aeovian.
NewLimit is the current capital-momentum leader. As seen above, its June 2026 $435 million Series C is the strongest fresh funding signal in therapeutic longevity. It does not yet beat Life Biosciences on human execution, but it has the clearest investor-backed attempt to build a broad reprogramming platform.
Life Biosciences is the current clinical-rejuvenation leader. Its June 2026 first human dosing makes it the most important company to watch for whether partial reprogramming can move from animal data into human safety. We rank it above older reprogramming incumbents because the signal is current, regulated, and testable.
Loyal is the current regulatory-commercial leader. It is working in dogs first, which limits direct human relevance, but its FDA CVM milestones are more concrete than most human longevity claims. If the question is “who can commercialize a lifespan-extension product first?”, Loyal is the most defensible answer.
Function Health is the consumer healthspan scale leader. It has the strongest combination of valuation, member disclosure, and product habit. Compared with Neko, it looks easier to scale repeatedly; compared with Superpower, it has more visible traction.
Neko Health is the premium preventive-health leader. Its waiting list and completed-scan count prove that consumers want a more proactive health experience. The key question is whether it can scale clinics without losing quality or creating too much medical follow-up burden.
Retro Biosciences remains a top moonshot. It does not lead on public clinical progress, but it does lead on ambition and has one of the strongest AI-biology signals in the category. That makes it more speculative than Life Biosciences, but still too important to leave out.
Rubedo Life Sciences is the underappreciated clinical biotech. Its Phase 1 senolytic data gives it more tangible human evidence than many better-known longevity startups. The narrower dermatology wedge is a feature, because it gives the company a realistic way to test senescence biology.
Timeline is the strongest evidence-backed consumer supplement company. It does not belong in the same risk category as NewLimit or Life Biosciences, but it beats most supplement peers because its Mitopure claim is supported by a much denser human-study base.
Superpower is the emerging consumer-healthspan challenger. It is earlier than Function, but its price point and biomarker dashboard fit where the market is moving now: accessible, repeatable, app-mediated preventive health.
Rejuvenate Bio is the emerging animal-gene-therapy challenger. Its Merck Animal Health collaboration is the signal that matters more than the financing size. It ranks behind Loyal because it is earlier, but above most animal-longevity names because it has incumbent validation.
Aeovian is the credible aging-pathway drug developer. It is less obviously “longevity-branded” than the others, but its mTORC1 program is clinically disciplined and tied to one of the most validated pathways in aging biology.
The broader conclusion is that longevity has split into four leaderboards. NewLimit and Retro define the moonshot layer. Life Biosciences, Rubedo, and Aeovian define the clinical-aging-biology layer. Loyal and Rejuvenate Bio define animal longevity. Function, Neko, Timeline, and Superpower define consumer healthspan. The strongest startups are the ones that keep showing up across recent funding, clinical, regulatory, and adoption signals, not the ones with the loudest promise of “living longer.”
If you want more recent data on this point, please see our latest longevity market report.
| Category | Startups selected and why |
|---|---|
| Closest to proving something in humans | Life Biosciences leads because it has first human dosing for partial reprogramming; Rubedo follows with fresh Phase 1 senolytic data; Aeovian is clinically ahead on a validated aging pathway; NewLimit and Retro remain pre-human or less transparent but highly relevant |
| Reprogramming leaders | Life Biosciences wins on first-in-human execution; NewLimit wins on fresh capital intensity; Retro wins on AI-enabled protein-design evidence; Altos remains the powerful but opaque incumbent |
| Strongest funding signal | NewLimit leads biotech funding; Function leads consumer-healthspan funding with disclosed member scale; Neko combines a large round with scan demand; Retro has the biggest reported ambition but less confirmed financing detail; Superpower is the lower-cost emerging challenger |
| Consumer longevity products | Function leads on recurring biomarker scale; Neko leads premium preventive scans; Superpower attacks affordability; Timeline has the strongest supplement evidence base; TruDiagnostic/Tally shows epigenetic-age-testing consolidation |
| Regulated commercial path | Loyal is closest to market through canine lifespan drugs; Life Biosciences has the top human rejuvenation milestone; Rubedo has a practical dermatology wedge; Aeovian has disciplined disease-led mTORC1 development; Rejuvenate Bio has Merck-backed animal-health validation |
| Animal longevity | Loyal is the clear leader because of FDA CVM progress; Rejuvenate Bio is the technical challenger because of its gene-therapy platform and Merck Animal Health collaboration |
| Diagnostics and biological age | Function leads the biomarker operating-system layer; Neko leads scan-based prevention; TruDiagnostic/Tally leads consolidation; Viome remains relevant in multi-omics; Superpower is the accessible challenger |
| AI-enabled longevity | Retro has the strongest specific AI-biology result; Function leads AI interpretation for consumers; NewLimit likely uses AI deeply but has less public proof; Viome has multi-omics AI relevance; Insilico is adjacent AI drug-discovery infrastructure |
| Under-discussed emerging names | Rubedo has fresher human evidence than its mindshare suggests; Rejuvenate Bio has new incumbent validation; Superpower is a low-cost consumer challenger; Aeovian is a disciplined aging-pathway biotech; TruDiagnostic/Tally shows consolidation; Midi Health is a practical midlife healthspan business |
| Less exciting right now | Altos is important but opaque; Cambrian needs a fresh asset-level milestone; BioAge was hit by azelaprag safety discontinuation; supplement-first brands without human data look weaker as the evidence bar rises |
OUR METHODOLOGY
This analysis tests which longevity startups look most credible today based on the evidence available now. We compare clinical, regulatory, funding, adoption, partnership, product, and scientific signals rather than treating “top longevity startup” as one broad category.
The longevity startup market is difficult to rank from intuition alone because different companies are proving different things. Some are closest to human clinical evidence, some have the strongest funding momentum, some are building consumer healthspan products, and others are advancing animal longevity, diagnostics, or AI-enabled biology.
To make the answer clearer, we broke the market into separate analytical dimensions. We looked at recent clinical progress, regulatory milestones, closed financing rounds, disclosed consumer adoption, named strategic partnerships, product maturity, and specific scientific proof points.
We gave the most weight to concrete, fresh evidence: first human dosing, Phase 1 data, FDA animal-health milestones, disclosed member scale, completed scans, closed financing rounds, named strategic partnerships, and specific AI-biology results.
We treated broader platform claims, historical prestige, and vague “anti-aging” positioning as weaker signals unless they were supported by recent external proof points. That is why some famous longevity companies rank below newer names with clearer current evidence.
The final ranking reflects structured aggregation rather than a single headline metric. Companies that appeared strong across multiple recent signals, or that clearly led one important dimension, were treated as more defensible top longevity startups than companies relying mainly on reputation, ambition, or category hype.
Key sources used for this analysis include: Life Biosciences on first patient dosed in the ER-100 Phase 1 trial, Wired on Life Biosciences’ first-in-human reprogramming milestone, Business Wire China on Rubedo’s RLS-1496 preliminary Phase 1 data, Business Wire on Aeovian’s $55 million raise and AV078 Phase 2 proof-of-concept plan, Yahoo Finance on NewLimit’s $435 million Series C and $3.1 billion valuation, OpenAI on its Retro Biosciences collaboration, PR Newswire on Altos Labs’ cellular rejuvenation launch, Chemical & Engineering News on Altos Labs’ $3 billion launch, PR Newswire on Function Health’s $2.5 billion valuation and Medical Intelligence Lab, TechCrunch on Function Health’s Series B and AI health-data layer, Neko Health on its $260 million Series B, scans, and waiting list, MedTech Dive on Neko Health’s scan demand and expansion, Business Wire on Loyal’s FDA CVM acceptance for LOY-002, Business Wire on Rejuvenate Bio’s financing and Merck Animal Health collaboration, Timeline on Mitopure’s 25th human clinical study milestone, Nature Aging on Urolithin A and immune-aging research, PR Newswire on Infinite Epigenetics’ acquisition of Tally Health, Fierce Healthcare on Superpower’s raise, price, and biomarker product, TechCrunch on Superpower’s preventive-health positioning, Business Insider on Midi Health’s scale and revenue run rate, Fierce Biotech on BioAge’s azelaprag discontinuation, and PR Newswire on Insilico Medicine’s Series E and AI drug-discovery positioning.
This chart, featured in our longevity market deck, illustrates how revenue is distributed across customer segments in the longevity market
Related blog posts
- How strong is fundraising in the longevity market right now?
- The startups that have raised the most funding in the longevity market
